{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T12:19:56Z","timestamp":1772281196637,"version":"3.50.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Sichuan Provincial International Science and Technology Innovation Cooperation","award":["2025YFHZ0110"],"award-info":[{"award-number":["2025YFHZ0110"]}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program","doi-asserted-by":"crossref","award":["2023YFB4606700"],"award-info":[{"award-number":["2023YFB4606700"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"name":"1\u00b73\u00b75 projects for Artificial Intelligence West China Hospital, Sichuan University","award":["ZYAI24038"],"award-info":[{"award-number":["ZYAI24038"]}]},{"name":"1\u00b73\u00b75 project for disciplines of excellence\u2013Clinical Research Fund, West China Hospital, Sichuan University","award":["2023HXFH024"],"award-info":[{"award-number":["2023HXFH024"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40261-025-01521-z","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T10:37:17Z","timestamp":1769596637000},"page":"243-258","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of the Efficacy of Denosumab and Alendronate in Improving Bone Mineral Density in Osteoporosis Patients and High-Risk Populations: A Systematic Review and Meta-Analysis"],"prefix":"10.1007","volume":"46","author":[{"given":"Kejia","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zongke","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6132-379X","authenticated-orcid":false,"given":"Yong","family":"Nie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"issue":"10169","key":"1521_CR1","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/S0140-6736(18)32112-3","volume":"393","author":"JE Compston","year":"2019","unstructured":"Compston JE, McClung MR, Leslie WD. Osteoporosis. Lancet. 2019;393(10169):364\u201376.","journal-title":"Lancet"},{"issue":"1","key":"1521_CR2","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1186\/s13018-021-02772-0","volume":"16","author":"N Salari","year":"2021","unstructured":"Salari N, et al. The global prevalence of osteoporosis in the world: a comprehensive systematic review and meta-analysis. J Orthop Surg Res. 2021;16(1):609.","journal-title":"J Orthop Surg Res"},{"issue":"3","key":"1521_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0248020","volume":"16","author":"MH Choi","year":"2021","unstructured":"Choi MH, et al. Prevalence and diagnosis experience of osteoporosis in postmenopausal women over 50: focusing on socioeconomic factors. PLoS ONE. 2021;16(3):e0248020.","journal-title":"PLoS ONE"},{"key":"1521_CR4","doi-asserted-by":"crossref","unstructured":"Osteoporosis prevention, diagnosis, and therapy. Jama 2001;285(6): 785-95.","DOI":"10.1001\/jama.285.6.785"},{"issue":"10","key":"1521_CR5","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1007\/s00198-021-05900-y","volume":"33","author":"MS LeBoff","year":"2022","unstructured":"LeBoff MS, et al. The clinician\u2019s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2022;33(10):2049\u2013102.","journal-title":"Osteoporos Int"},{"issue":"8","key":"1521_CR6","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1007\/s11547-024-01843-6","volume":"129","author":"C Messina","year":"2024","unstructured":"Messina C, et al. DXA beyond bone mineral density and the REMS technique: new insights for current radiologist\u2019s practice. Radiol Med. 2024;129(8):1224\u201340.","journal-title":"Radiol Med"},{"issue":"2","key":"1521_CR7","doi-asserted-by":"publisher","first-page":"224","DOI":"10.7326\/M22-1034","volume":"176","author":"A Qaseem","year":"2023","unstructured":"Qaseem A, et al. Pharmacologic treatment of primary osteoporosis or low bone mass to prevent fractures in adults: a living clinical guideline from the American College of Physicians. Ann Intern Med. 2023;176(2):224\u201338.","journal-title":"Ann Intern Med"},{"key":"1521_CR8","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa048","author":"D Shoback","year":"2020","unstructured":"Shoback D, et al. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society guideline update. J Clin Endocrinol Metab. 2020. https:\/\/doi.org\/10.1210\/clinem\/dgaa048.","journal-title":"J Clin Endocrinol Metab"},{"key":"1521_CR9","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2024.2252","author":"KJ Kim","year":"2025","unstructured":"Kim KJ, et al. Comprehensive evaluation of treatment patterns in postmenopausal patients with osteoporosis without fractures: insights from tertiary care institutions and nationwide OMOP-CDM data. Endocrinol Metab (Seoul). 2025. https:\/\/doi.org\/10.3803\/EnM.2024.2252.","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"5","key":"1521_CR10","doi-asserted-by":"publisher","first-page":"564","DOI":"10.4158\/GL-2020-0524","volume":"26","author":"PM Camacho","year":"2020","unstructured":"Camacho PM, et al. American Association Of Clinical Endocrinologists\/American College Of Endocrinology Clinical Practice Guidelines For The Diagnosis And Treatment Of Postmenopausal Osteoporosis 2020 Update Executive Summary. Endocr Pract. 2020;26(5):564\u201370.","journal-title":"Endocr Pract"},{"issue":"8","key":"1521_CR11","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756\u201365.","journal-title":"N Engl J Med"},{"issue":"3","key":"1521_CR12","doi-asserted-by":"publisher","first-page":"415","DOI":"10.2165\/00003495-199753030-00006","volume":"53","author":"W Jeal","year":"1997","unstructured":"Jeal W, Barradell LB, McTavish D. Alendronate. A review of its pharmacological properties and therapeutic efficacy in postmenopausal osteoporosis. Drugs. 1997;53(3):415\u201334.","journal-title":"Drugs"},{"issue":"1","key":"1521_CR13","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.bone.2011.01.014","volume":"49","author":"S Cremers","year":"2011","unstructured":"Cremers S, Papapoulos S. Pharmacology of bisphosphonates. Bone. 2011;49(1):42\u20139.","journal-title":"Bone"},{"issue":"8","key":"1521_CR14","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1002\/jbmr.403","volume":"26","author":"SA Jamal","year":"2011","unstructured":"Jamal SA, et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res. 2011;26(8):1829\u201335.","journal-title":"J Bone Miner Res"},{"key":"1521_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g7647","volume":"350","author":"L Shamseer","year":"2015","unstructured":"Shamseer L, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;350:g7647.","journal-title":"BMJ"},{"key":"1521_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"key":"1521_CR17","unstructured":"Higgins JPT, T.J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024). Cochrane, 2024. Available from www.cochrane.org\/handbook."},{"issue":"8","key":"1521_CR18","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1056\/NEJMoa044459","volume":"354","author":"MR McClung","year":"2006","unstructured":"McClung MR, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006;354(8):821\u201331.","journal-title":"N Engl J Med"},{"issue":"12","key":"1521_CR19","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1359\/jbmr.070809","volume":"22","author":"EM Lewiecki","year":"2007","unstructured":"Lewiecki EM, et al. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res. 2007;22(12):1832\u201341.","journal-title":"J Bone Miner Res"},{"issue":"3","key":"1521_CR20","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jocd.2008.04.001","volume":"11","author":"TJ Beck","year":"2008","unstructured":"Beck TJ, et al. Effects of denosumab on the geometry of the proximal femur in postmenopausal women in comparison with alendronate. J Clin Densitom. 2008;11(3):351\u20139.","journal-title":"J Clin Densitom"},{"issue":"1","key":"1521_CR21","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1359\/jbmr.0809010","volume":"24","author":"JP Brown","year":"2009","unstructured":"Brown JP, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res. 2009;24(1):153\u201361.","journal-title":"J Bone Miner Res"},{"issue":"1","key":"1521_CR22","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s00198-011-1780-1","volume":"23","author":"N Freemantle","year":"2012","unstructured":"Freemantle N, et al. Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int. 2012;23(1):317\u201326.","journal-title":"Osteoporos Int"},{"issue":"3","key":"1521_CR23","first-page":"271","volume":"69","author":"C Doria","year":"2017","unstructured":"Doria C, et al. Treatment of osteoporosis secondary to hypogonadism in prostate cancer patients: a prospective randomized multicenter international study with denosumab vs. alendronate. Minerva Urol Nefrol. 2017;69(3):271\u20137.","journal-title":"Minerva Urol Nefrol"},{"issue":"3","key":"1521_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0193846","volume":"13","author":"K Iseri","year":"2018","unstructured":"Iseri K, et al. The effects of denosumab and alendronate on glucocorticoid-induced osteoporosis in patients with glomerular disease: a randomized, controlled trial. PLoS ONE. 2018;13(3):e0193846.","journal-title":"PLoS ONE"},{"issue":"6","key":"1521_CR25","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1002\/jbmr.3676","volume":"34","author":"K Iseri","year":"2019","unstructured":"Iseri K, et al. Effects of denosumab and alendronate on bone health and vascular function in hemodialysis patients: a randomized, controlled trial. J Bone Miner Res. 2019;34(6):1014\u201324.","journal-title":"J Bone Miner Res"},{"key":"1521_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2021.115902","volume":"146","author":"CC Mok","year":"2021","unstructured":"Mok CC, et al. Denosumab versus alendronate in long-term glucocorticoid users: a 12-month randomized controlled trial. Bone. 2021;146:115902.","journal-title":"Bone"},{"issue":"7","key":"1521_CR27","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1210\/jc.2013-4175","volume":"99","author":"T Nakamura","year":"2014","unstructured":"Nakamura T, et al. Clinical trials express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT). J Clin Endocrinol Metab. 2014;99(7):2599\u2013607.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1521_CR28","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1359\/jbmr.090716","volume":"25","author":"DL Kendler","year":"2010","unstructured":"Kendler DL, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res. 2010;25(1):72\u201381.","journal-title":"J Bone Miner Res"},{"issue":"6","key":"1521_CR29","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1007\/s00198-010-1378-z","volume":"22","author":"DL Kendler","year":"2011","unstructured":"Kendler DL, et al. Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate. Osteoporos Int. 2011;22(6):1725\u201335.","journal-title":"Osteoporos Int"},{"issue":"5","key":"1521_CR30","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/jbm4.10054","volume":"2","author":"R Niimi","year":"2018","unstructured":"Niimi R, et al. Efficacy of switching from teriparatide to bisphosphonate or denosumab: a prospective, randomized, open-label trial. JBMR Plus. 2018;2(5):289\u201394.","journal-title":"JBMR Plus"},{"issue":"2","key":"1521_CR31","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ecl.2021.03.009","volume":"50","author":"RM Arceo-Mendoza","year":"2021","unstructured":"Arceo-Mendoza RM, Camacho PM. Postmenopausal osteoporosis: latest guidelines. Endocrinol Metab Clin North Am. 2021;50(2):167\u201378.","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"4","key":"1521_CR32","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1097\/GRF.0000000000000572","volume":"63","author":"M Mu\u00f1oz","year":"2020","unstructured":"Mu\u00f1oz M, Robinson K, Shibli-Rahhal A. Bone health and osteoporosis prevention and treatment. Clin Obstet Gynecol. 2020;63(4):770\u201387.","journal-title":"Clin Obstet Gynecol"},{"key":"1521_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242115772","author":"IV Zhivodernikov","year":"2023","unstructured":"Zhivodernikov IV, et al. Molecular and cellular mechanisms of osteoporosis. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms242115772.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"1521_CR34","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1007\/s11914-021-00702-x","volume":"19","author":"LM McNamara","year":"2021","unstructured":"McNamara LM. Osteocytes and estrogen deficiency. Curr Osteoporos Rep. 2021;19(6):592\u2013603.","journal-title":"Curr Osteoporos Rep"},{"issue":"7","key":"1521_CR35","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1093\/jbmr\/zjae079","volume":"39","author":"JR Curtis","year":"2024","unstructured":"Curtis JR, et al. Comparative effectiveness of denosumab vs alendronate among postmenopausal women with osteoporosis. J Bone Miner Res. 2024;39(7):826\u201334.","journal-title":"J Bone Miner Res"},{"issue":"4","key":"1521_CR36","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/j.1742-1241.2011.02806.x","volume":"66","author":"T Lin","year":"2012","unstructured":"Lin T, et al. Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta-analysis. Int J Clin Pract. 2012;66(4):399\u2013408.","journal-title":"Int J Clin Pract"},{"issue":"11","key":"1521_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2012.15","volume":"1","author":"MC Peterson","year":"2012","unstructured":"Peterson MC, Riggs MM. Predicting nonlinear changes in bone mineral density over time using a multiscale systems pharmacology model. CPT Pharmacometrics Syst Pharmacol. 2012;1(11):e14.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"9","key":"1521_CR38","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1002\/psp4.12324","volume":"7","author":"C Hasegawa","year":"2018","unstructured":"Hasegawa C, Duffull SB. Automated scale reduction of nonlinear QSP models with an illustrative application to a bone biology system. CPT Pharmacometrics Syst Pharmacol. 2018;7(9):562\u201372.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"7","key":"1521_CR39","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","volume":"5","author":"HG Bone","year":"2017","unstructured":"Bone HG, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5(7):513\u201323.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"1521_CR40","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1210\/jc.2016-1160","volume":"101","author":"JN Tsai","year":"2016","unstructured":"Tsai JN, et al. Effects of two years of teriparatide, denosumab, or both on bone microarchitecture and strength (DATA-HRpQCT study). J Clin Endocrinol Metab. 2016;101(5):2023\u201330.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1521_CR41","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1007\/s00774-020-01147-5","volume":"39","author":"A Miyauchi","year":"2021","unstructured":"Miyauchi A, et al. Romosozumab followed by denosumab in Japanese women with high fracture risk in the FRAME trial. J Bone Miner Metab. 2021;39(2):278\u201388.","journal-title":"J Bone Miner Metab"},{"issue":"4","key":"1521_CR42","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1210\/jc.2010-1502","volume":"96","author":"HG Bone","year":"2011","unstructured":"Bone HG, et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab. 2011;96(4):972\u201380.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1521_CR43","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1210\/jc.2016-3170","volume":"102","author":"O Lamy","year":"2017","unstructured":"Lamy O, et al. Severe rebound-associated vertebral fractures after denosumab discontinuation: 9 clinical cases report. J Clin Endocrinol Metab. 2017;102(2):354\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1521_CR44","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s10198-018-1011-1","volume":"20","author":"JY Matuoka","year":"2019","unstructured":"Matuoka JY, Kahn JG, Secoli SR. Denosumab versus bisphosphonates for the treatment of bone metastases from solid tumors: a systematic review. Eur J Health Econ. 2019;20(4):487\u201399.","journal-title":"Eur J Health Econ"},{"issue":"1","key":"1521_CR45","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/jbmr.2325","volume":"30","author":"KE Poole","year":"2015","unstructured":"Poole KE, et al. Denosumab rapidly increases cortical bone in key locations of the femur: a 3D bone mapping study in women with osteoporosis. J Bone Miner Res. 2015;30(1):46\u201354.","journal-title":"J Bone Miner Res"},{"issue":"8","key":"1521_CR46","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1002\/jbmr.81","volume":"25","author":"E Seeman","year":"2010","unstructured":"Seeman E, et al. Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res. 2010;25(8):1886\u201394.","journal-title":"J Bone Miner Res"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01521-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-025-01521-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01521-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T11:36:36Z","timestamp":1772278596000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-025-01521-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1521"],"URL":"https:\/\/doi.org\/10.1007\/s40261-025-01521-z","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]},"assertion":[{"value":"23 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kejia Zhu, Hang Li, Hui Zhang, Zongke Zhou, Bin Shen, and Yong Nie declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Conceptualisation, Kejia Zhu, Hui Zhang and Hang Li; Data curation, Kejia Zhu, Hui Zhang and Yong Nie; Formal analysis, Zongke Zhou and Yong Nie; Funding acquisition, Yong Nie; Methodology, Kejia Zhu, Hui Zhang and Yong Nie; Project administration, Zongke Zhou, Bin Shen and Yong Nie; Resources, Bin Shen and Yong Nie; Software, Kejia Zhu and Hang Li; Supervision, Zongke Zhou, Bin Shen and Yong Nie; Validation, Yong Nie; Visualisation, Kejia Zhu and Hang Li; Writing\u2014original draft, Kejia Zhu, Hui Zhang and Hang Li; Writing\u2014review & editing, Zongke Zhou, Bin Shen and Yong Nie. All authors read and approved the final version and agree to be accountable for the work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The datasets generated during and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}